Amyloid-Tau Interaction Hypothesis
Amyloid plaques may drive downstream tau pathology spread.
- Upstream: Amyloid cascade (placeholder fact)
- Downstream: Tau spread (placeholder fact)
- Early stage: Interaction window (placeholder fact)
- Preclinical: Evidence base (placeholder fact)
Biological rationale for dual targeting
Placeholder: amyloid may trigger and accelerate tau pathology spread.
Placeholder highlight: interaction hypothesis motivates combination approach.
Sequential vs Simultaneous Dosing
Comparing anti-amyloid-first sequencing against simultaneous dual dosing.
- Amyloid→Tau: Sequential arm (placeholder fact)
- Both agents: Simultaneous arm (placeholder fact)
- Variable: Washout period (placeholder fact)
- Continuous: Safety monitoring (placeholder fact)
Dosing order considerations
Placeholder: sequencing may affect combined safety and efficacy outcomes.
Placeholder highlight: dosing order remains an open design question.
Dual-Target Trial Design
Trial architecture needed to evaluate combined dual-target therapy.
- 4-arm factorial: Arms (placeholder fact)
- Placeholder: Enrollment target (placeholder fact)
- 18-24 months: Duration (placeholder fact)
- Cognitive + biomarker: Endpoint type (placeholder fact)
Factorial trial architecture
Placeholder: factorial design isolates individual and combined effects.
Placeholder highlight: dual-target trials require larger sample sizes.
Combined Biomarker Monitoring
Monitoring amyloid and tau biomarkers jointly across treatment.
- PET / CSF: Amyloid marker (placeholder fact)
- PET / p-tau217: Tau marker (placeholder fact)
- Periodic: Sampling frequency (placeholder fact)
- Dual panel: Panel breadth (placeholder fact)
Dual biomarker panel rationale
Placeholder: joint biomarker tracking clarifies mechanism-specific response.
Placeholder highlight: combined panels detect divergent target engagement.
Additive vs Synergistic Outcome Assessment
Statistical models distinguish additive from synergistic combined benefit.
- Sum of effects: Additive model (placeholder fact)
- Interaction term: Synergy model (placeholder fact)
- Interaction ANOVA: Statistical test (placeholder fact)
- Cognitive decline: Outcome measure (placeholder fact)
Distinguishing additive from synergistic effects
Placeholder: interaction term testing separates additive from synergistic gains.
Placeholder highlight: synergy would exceed sum of monotherapy effects.